Journal Information
Vol. 43. Issue. 1.January - February 2023
Pages 1-160
Vol. 43. Issue. 1.January - February 2023
Pages 1-160
Letter to the Editor
Full text access
Comments on the consensus document on autosomal dominant polycystic kidney disease of the SENefro
Comentarios sobre el Documento de consenso de poliquistosis renal autosómica dominante de la SENefro
José Ignacio Minguela
Corresponding author
Servicio de Nefrología, Hospital Universitario Basurto, Bilbao, Bizkaia, Spain
This item has received
Article information
Full Text
Download PDF
Full Text
Dear Editor,

I have read the Consensus Document on Autosomal Dominant Polycystic Kidney1 that the Spanish Society of Nephrology (Sociedad Española de Nefrología, SEN) drafted and published on its website and I would like to make some of comments on what has been exposed in that document.

They are based on the lack of definition of the term “rapid progressor” by the EMA2 to establish some criteria that seem to me to be inaccurate. Anyone who starts renal replacement therapy before the mean global age for starting renal replacement therapy in Spain (65 years old) is considered a rapid progressor. If a disease takes an average of X years to reach the terminal stage, the rapid progressors would be all those patients who reach that point before that X average, and slow progressors, who last longer than the average for that process. I believe that the overall average age at initiation of renal replacement therapy should not be used as a reference point since other diseases present at more advanced ages (diabetic nephropathy and nephroangiosclerosis) have an impact and therefore increase that average age. According to the logic used by the authors, it could also be said that any person who starts dialysis before the average life expectancy of the general population (80.6 years in men and 86 in women before the pandemic)3 is a rapid progressor. Therefore most of our patients could be included in that definition. In type 1 polycystic kidney disease, the average onset of end-stage kidney failure is 54 years old,4,5 and that should be, in my opinion, the point at which a person with polycystic disease is considered a rapid or slow progressor.

In addition, it is suggested to start treatment with tolvaptan in patients until 60 years old. I have only seen one study6 (REPRISE) including patients >55 years. In that study, in the subgroup of patients >55 years old, the difference in progression was similar with respect to the placebo group (GFR drop: 2.54 vs 2.34ml/min [p=0.65]). The study included a limited number of patients, but no other study affirms otherwise; therefore, no treatment should be started at these ages outside of a controlled clinical trial.

I believe that the society allows us to manage public funds, that are limited, with a commitment to maximum efficiency. That means using them in those cases in which these treatments are truly useful. If we cannot manage these funds, we will totally lose the capacity of managing them.

Ars E, Bernis C, Fraga C, Furlano M, Martínez V, Martins J, et al. Documento de consenso de poliquistosis renal autosómica dominante. [Accessed 16 March 2021]. Available from:
Ficha técnica Jinarc en EMA. [Accessed 16 March 2021]. Available from:
M.V. Irazabal, V.E. Torres.
Poliquistosis renal autosómica dominante.
Nefrología suplemento Extraordinario, 2 (2011), pp. 38-51
A.I. Morales García, M. Martínez Atienza, M. García Valverde, J. Fontes Jiménez, A. Martínez Morcillo, M.A. Esteban de la Rosa, et al.
Panorámica de la poliquistosis renal autosómica dominante en una región del sur de España.
Nefrología, 38 (2018), pp. 190-196
V.E. Torres, A.B. Chapman, O. Devuyst, R.T. Gansevoort, R.D. Perrone, G. Koch, et al.
Tolvaptan in later stage autosomal dominant polycystic kidney disease.
N Engl J Med, 377 (2017), pp. 1930-1942
Copyright © 2021. Sociedad Española de Nefrología
Nefrología (English Edition)
Article options
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?